When the U.S. FDA’s vaccine committee endorsed the Maryland-produced protein-based COVID-19 vaccine on June 7, 2022, many people expected authorization would immediately follow.
However, according to Novavax Inc.’s statement issued on July 1, 2022, this World Health Organization Listed vaccine remains under FDA review.
Novavax stated ‘it is awaiting U.S. emergency use authorization (EUA) for our prototype COVID-19 vaccine, and we are committed to bringing it to market.
Will the FDA Ever Authorize a Protein-Based COVID-19 Vaccine?
No Room for Monkeypox Outbreak Complacency
The World Health Organization (WHO) reaffirmed its call today for governments and civil society to scale up efforts to prevent the monkeypox outbreak from establishing itself across additional geographical areas.
The WHO’s Regional Director for Europe, Dr. Hans Henri P. Kluge, stated on July 1, 2022, “Urgent and coordinated action is imperative if we are to turn a corner in the race to reverse the ongoing spread of this disease.”
Provider Availability Linked to COVID-19 Vaccine Uptake in Children
Vaccination coverage for children aged 5 to 11 higher in counties with at least one active COVID-19 vaccine provider versus no provider
New York City First to Offer Paxlovid at COVID-19 Testing Sites
‘Test-to-Treat’ program is part of federal and city efforts to catch and treat infections early and be ready for new waves of the pandemic
Injuries From Fireworks on the Rise in the United States
Fireworks-related injuries and deaths in the U.S. have climbed by about 25 percent over the past 15 years
Headaches in Teens During Pandemic Tied to Depression, Anxiety
Among teens with headache, 27 percent reported worsening of headaches, while 10 percent had new onset of headache
Vaccination Protects Overweight, Obese Against Severe COVID-19
Protection against severe COVID-19 similar for those with overweight, obesity versus healthy weight; lower protection seen for underweight